Results 41 to 50 of about 7,932,688 (301)

Human African trypanosomiasis : current status and eradication efforts [PDF]

open access: yes, 2020
Epidemics of human African trypanosomiasis (HAT) in the 20th century led to millions of deaths. However, since the start of the twenty-first century, there is been a continued decline in the number of reported cases, due to increased investment and ...
Davis, Christopher   +2 more
core   +1 more source

A PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT A second allogeneic (allo‐)hematopoietic stem cell transplantation (HSCT2) is a potential curative option for pediatric patients with acute lymphoblastic leukemia (ALL) following relapse after first allogeneic transplantation (HSCT1), but its efficacy is limited by high relapse rates and transplant‐related toxicity in highly pretreated ...
Ava Momm   +10 more
wiley   +1 more source

The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2014

open access: yesEFSA Journal, 2016
The data on antimicrobial resistance in zoonotic and indicator bacteria in 2014, submitted by 28 EU Member States (MSs), were jointly analysed by EFSA and ECDC.
European Food Safety Authority   +1 more
doaj   +1 more source

Biological Terrorism [PDF]

open access: yes, 2008
In the aftermath of the September 11, 2001 attacks and the subsequent mail-borne anthrax attack of October 2001, it has become dear that health care providers may be called upon to respond to victims of terrorism. Biological terrorism (BT), in particular,
Centers for Disease Control and Prevention   +4 more
core   +2 more sources

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender   +17 more
wiley   +1 more source

Infectious Disease Surveillanc

open access: yesIranian Journal of Microbiology, 2009
No ...
Iranian Center for Disease Control
doaj  

The European Union Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2010

open access: yesEFSA Journal, 2012
The antimicrobial resistance data on zoonotic and indicator bacteria in 2010, submitted by 26 European Union Member States, were jointly analysed by the European Food Safety Authority and the European Centre for Disease Prevention and Control.
European Food Safety Authority   +1 more
doaj   +1 more source

Incidence and Risk Factors of Serious Osteonecrosis in Pediatric Acute Lymphoblastic Leukemia: A CYP‐C Population‐Based Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Osteonecrosis (ON) is a debilitating complication of acute lymphoblastic leukemia (ALL) therapy. While numerous studies have explored its incidence and associated risk factors, investigations using large‐scale cohorts remain important to characterize ON across heterogeneous populations.
Noémie de Villiers   +5 more
wiley   +1 more source

Infections Disease Surveillance

open access: yesIranian Journal of Microbiology, 2009
No ...
Iranian Center for Disease Control
doaj  

The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2015

open access: yesEFSA Journal, 2017
The data on antimicrobial resistance in zoonotic and indicator bacteria in 2015, submitted by 28 EU Member States (MSs), were jointly analysed by EFSA and ECDC.
European Food Safety Authority   +1 more
doaj   +1 more source

Home - About - Disclaimer - Privacy